GlucoTrack Inc. Completes Strategic Business Combination and Bridge Financing

GlucoTrack Inc. (Nasdaq: GCTK) announced the successful completion of a strategic business combination with Lōkahi Therapeutics on July 16 2026. The transaction, which has been reported by multiple financial outlets, positions GlucoTrack as a publicly listed, capital‑efficient platform while granting Lōkahi Therapeutics control of the newly merged entity.

Transaction Structure

  • Ownership: Upon final stock‑holder approvals and Nasdaq listing requirements, the combined company is expected to be controlled by Lōkahi Therapeutics, holding approximately 90 % of the fully diluted equity after conversion of the issued convertible preferred stock.
  • Capital Efficiency: The deal was structured to leverage GlucoTrack’s public market platform for capital access. A planned private placement is underway to bolster the company’s balance sheet and fund near‑term execution.
  • Dedicated Subsidiary: GlucoTrack’s continuous blood glucose monitoring (CBGM) technology will operate as a wholly owned subsidiary, preserving its asset structure and allowing focused development.

Leadership and Governance

  • Erik Emerson has been appointed Chief Executive Officer of the combined company, tasked with providing unified leadership and strategic direction.
  • Paul Goode will serve as Chief Technical Officer of the combined organization and as Chief Executive Officer of the CBGM subsidiary, ensuring continuity of technical oversight.

Strategic Rationale

The combination aligns Lōkahi Therapeutics’ dual‑engine model—late‑stage clinical development and an AI‑driven asset sourcing platform—with GlucoTrack’s existing technology infrastructure. The integrated framework is intended to create a scalable, repeatable model for value creation across the healthcare sector.

Bridge Financing

Following the merger, GlucoTrack completed a bridge financing round. The transaction was supported by E.F. Hutton & Co., the exclusive financial advisor in the combination. The financing is aimed at strengthening the capital position of the merged entity and supporting its execution strategy.

Market Reaction

After the announcement, GlucoTrack’s stock experienced a notable after‑hours rally of 16 %, reflecting investor enthusiasm for the combined platform’s growth prospects. The positive market response underscores confidence in the strategic fit and the anticipated synergies between the two companies.

Summary

GlucoTrack’s successful completion of both a strategic business combination with Lōkahi Therapeutics and a bridge financing round marks a pivotal moment for the company. By integrating advanced medical device technology with a robust, AI‑driven development model, the newly formed entity is poised to accelerate the identification, acquisition, and advancement of differentiated healthcare assets while maintaining a lean, publicly listed structure.